Ocugen to present 12-month Phase 2 ArMaDa trial results for OCU410 gene therapy in geographic atrophy at AAO 2026

By Public Technologies
  • Ocugen flagged upcoming presentations of clinical trial results for its modifier gene therapies in eye diseases.
  • Phase 2 ArMaDa trial readouts for OCU410 in geographic atrophy are scheduled for Oct. 9 and Oct. 11, 2026.
  • Management framed the ArMaDa update as covering safety and efficacy outcomes over 12 months, with no metrics disclosed.
  • Phase 1/2 GARDian1 results for OCU410ST in Stargardt disease will also be presented in early October 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocugen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609300702PRIMZONEFULLFEED9836569) on September 30, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk